(917) 310-3371
Cancer screening looks for disease in people who do not have symptoms. Different tests target different cancers and apply to different risk groups. A screening visit reviews your age, history, prior tests and preferences to choose an appropriate plan. Symptoms or an abnormal screening result need diagnostic assessment rather than another routine screen.
A stool DNA test such as Cologuard, a PSA blood test, low-dose CT lung screening and a multi-cancer blood test do different jobs. A positive result is not by itself a cancer diagnosis. A negative result cannot rule out all cancer. Screening can also produce false positives, unnecessary procedures and overdiagnosis, so benefits and harms should be discussed.
USPSTF recommends colorectal screening for average-risk adults ages 45–75 and individual decisions at 76–85. Its lung recommendation covers ages 50–80 with at least 20 pack-years who currently smoke or quit within 15 years. PSA screening at ages 55–69 is an individual decision under USPSTF; routine screening at 70 or older is not recommended by that guideline. Other organizations may differ, and individual risks matter.
Review previous screening, family history, smoking exposure and symptoms. The clinician explains the recommended test, alternatives, possible results and follow-up. Cologuard is intended for selected average-risk screening; a positive stool screening result requires colonoscopy. High-risk history or concerning symptoms may require a different route from a mail-in stool test.
Bring prior reports and a family cancer history. Ask for the exact collection or imaging instructions. Some stool tests need a supplied kit, while colonoscopy has separate preparation. Tell the team about blood in stool, unexplained weight loss, a persistent new symptom or a previous abnormal result rather than presenting only a request for screening.
Galleri and other multi-cancer detection tests remain distinct from established guideline screening. The current manufacturer and NCI materials reviewed do not establish FDA approval of Galleri; an advisory panel vote is not approval. Such testing does not replace recommended breast, cervical, colorectal or eligible lung screening. Severe bleeding, marked breathing difficulty or other acute symptoms need urgent care.
Before testing, agree on who will review the result and arrange diagnostic follow-up. A positive multi-cancer signal can lead to additional testing without finding cancer. A negative result does not end recommended screening or assessment of symptoms. Track referrals until the receiving practice confirms the next step.
Confirm which tests Nao actually orders or collects, where imaging or colonoscopy occurs and who manages abnormal results. Ask about the test, visit and diagnostic follow-up costs separately.
Start with the screening or symptom concern that matters most to you and bring prior results and family history. The clinician can identify which age- and risk-based screenings are due and which tests or referrals need a separate service. Not every test is performed in the same visit or onsite. An abnormal result needs a named follow-up plan.
Check the exact insurance product, clinician, location and service with both the office and insurer. A company name, Medicaid or Medicare alone does not establish that every plan is in network. Ask about the visit and test or procedure separately, your copay or deductible, and any referral or authorization requirement. Coverage is not a guarantee of no charge.
A primary care discussion can review several screening questions together, but each test has its own age, risk, timing and follow-up requirements. Bring prior Pap/HPV, stool, colonoscopy or PSA reports. False-positive and false-negative Galleri results are possible. Galleri is not FDA-cleared or approved and does not replace those recommended screenings. Confirm which tests or referrals can actually be arranged and their charges.
A Pap test looks for abnormal cervical cells; it is screening, not a cervical cancer diagnosis. An abnormal result can need follow-up such as repeat testing, HPV testing or colposcopy according to the result and history. Bring prior Pap and HPV reports. Confirm whether the clinic performs sample collection or arranges a separate appointment.
A positive Cologuard result is a screening finding, not a cancer diagnosis. A diagnostic colonoscopy is needed to investigate it; repeating a stool test does not settle the result. Contact the ordering clinician for the referral and follow-up plan. Many positive results have causes other than cancer, but they must not be ignored.
PSA is a blood test used in a prostate cancer screening discussion; it does not diagnose cancer by itself. USPSTF recommends an individual decision for men age 55–69 after discussing benefits and harms, and recommends against routine screening at age 70 or older. Risk and previous results can change the clinical discussion. Bring records and decide with the clinician rather than assuming every adult needs PSA.
USPSTF recommends annual low-dose CT screening for adults age 50–80 with at least a 20 pack-year smoking history. They must currently smoke or have quit within the past 15 years. A pack-year is packs per day multiplied by years smoked. Bring smoking dates and prior imaging; quitting longer ago changes eligibility under this recommendation. Discuss smoking cessation, risks and the imaging referral with the clinician. New symptoms require a diagnostic pathway.
New symptoms need diagnostic assessment rather than only a routine screening test. Tell the clinician about bleeding, a new lump, persistent unexplained pain, bowel changes or unexplained weight loss. A negative screening result does not rule out the cause. Heavy bleeding or severe abdominal pain needs emergency department care now. Call 911 for bleeding that will not stop, fainting, severe breathing difficulty or unsafe travel. Other new or continuing symptoms need diagnostic assessment.
Bring actual reports with dates, prior biopsy or pathology results, screening records and details of family history. They help the clinician avoid duplicate tests and choose the correct screening or follow-up interval. An abnormal outside result needs its specific diagnostic follow-up; it should not be replaced by a general screening package.
Cervical screening looks for high-risk HPV infection or abnormal cervical cells before symptoms develop. An HPV test detects specified virus types, while a Pap test examines cells. Depending on age, history and the recommended pathway, these may be used separately or together. An abnormal screening result is not itself a cancer diagnosis and can require repeat testing or colposcopy. Screening intervals and follow-up differ for prior abnormal results, immune suppression and other risks. Bring previous reports and ask whether the service collects the sample or arranges it elsewhere. Unexplained bleeding needs diagnostic assessment rather than waiting for routine screening.
Ask your local health department, insurer or a dermatology service whether a current screening event or assistance program is available and what it includes. Confirm any current free program and its scope with the organizer before traveling. NCI reports that evidence is insufficient to establish that routine skin screening reduces deaths in the general population. That uncertainty does not mean an unusual lesion should be ignored. A new, changing, bleeding or otherwise concerning spot needs clinical assessment, which is a different task from a free screening event. Ask about the examination, biopsy referral and any separate charges.
Use the Cologuard page for direct at-home colorectal-screening booking and follow-up planning.
Compare stool-based screening and colonoscopy options with clear next-step guidance.
Review multi-cancer early-detection planning, who may consider Galleri, and what it does not replace.
Use the cervical-screening page for Pap smear questions, HPV co-testing context, and local women's-health clinic access.
Handle prostate-screening timing, shared-decision questions, and PSA blood-test planning through primary care.
Check low-dose CT eligibility, smoking-history thresholds, and how screening conversations can start locally.